NCT06812871 2026-04-02
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Sun Yat-sen University
Phase 2 Completed
Clinical Trials
5 trialsNCT05805631 2026-03-24
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Taipei Veterans General Hospital, Taiwan
Phase 2 Recruiting
NCT06296745 2026-01-30
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
Guangzhou Medical University
Phase 2 Recruiting
NCT06861218 2025-03-06
Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT05810350 2023-04-13
Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles
Three Gorges Hospital of Chongqing University
Phase 2 Unknown